Top

Journal of Endocrinological Investigation

Published in:

01-07-2018 | Short Review

Pituitary adenomas, stem cells, and cancer stem cells: what’s new?

Authors: M. Caffarini, M. Orciani, L. Trementino, R. Di Primio, G. Arnaldi

Published in: Journal of Endocrinological Investigation | Issue 7/2018

Abstract

Purpose

To clarify the existence of pituitary stem cells (SCs) both in the embryonic and the postnatal gland and the role for SCs in pituitary adenomas.

Methods

This work, which does not address the pathogenesis of pituitary adenomas, reviews the latest research findings and discoveries on SCs in pituitary and cancer SCs (CSCs) in pituitary adenomas and discusses the involvement of the EMT.

Results

Several groups using different approaches and techniques have demonstrated the existence of SCs and CSCs and as they are major players in pituitary adenoma onset.

Conclusions

As in other benign and malignant tumors, the hypothesis that CSCs play a pivotal role in pituitary adenoma onset has been confirmed as well as the existence of a link between the epithelial-to-mesenchymal transition (EMT) process and CSC formation in epithelial tumors.

Melmed S (2003) Mechanisms for pituitary tumorigenesis: the plastic pituitary. J Clin Invest 112:1603–1618. https://doi.org/10.1172/JCI20401 CrossRefPubMedPubMedCentral

Denef C (2008) Paracrinicity: the story of 30 years of cellular pituitary crosstalk. J Neuroendocrinol 20:1–70. https://doi.org/10.1111/j.1365-2826.2007.01616 CrossRefPubMedPubMedCentral

Vankelecom H (2010) Pituitary stem/progenitor cells: embryonic players in the adult gland? Eur J Neurosci 32:2063–2081. https://doi.org/10.1111/j.1460-9568.2010.07523 CrossRefPubMed

Karavitaki N (2012) Prevalence and incidence of pituitary adenomas. Ann Endocrinol (Paris) 73:79–80. https://doi.org/10.1016/j.ando.2012.03.039 CrossRef

Fernandez A, Karavitaki N, Wass JA (2010) Prevalence of pituitary adenomas: a community based, cross-sectional study in Banbury. Clin Endocrinol (Oxf) 72:377–382. https://doi.org/10.1111/j.1365-2265.2009.03667.x CrossRef

Raappana A, Koivukangas J, Ebeling T, Pirila T (2010) Incidence of pituitary adenomas in Northern Finland in 1992–2007. J Clin Endocrinol Metab 95:4268–4275. https://doi.org/10.1210/jc.2010-0537 CrossRefPubMed

Melmed S (2011) Pathogenesis of pituitary tumors. Nat Rev Endocrinol 7:257–266. https://doi.org/10.1038/nrendo.2011.40 CrossRefPubMed

Ullah I, Baregundi Subbarao R, Jin Rho G (2015) Human mesenchymal stem cells—current trends and future prospective. Biosci Rep 35:e00191. https://doi.org/10.1042/BSR20150025 CrossRefPubMedPubMedCentral

Fauquier T, Rizzoti K, Dattani M, Lovell-Badge R, Robinson IC (2008) SOX²- expressing progenitor cells generate all of the major cell types in the adult mouse pituitary gland. Proc Natl Acad Sci USA 105:2907–2912. https://doi.org/10.1073/pnas.0707886105 CrossRefPubMedPubMedCentral

10.

Chen J, Hersmus N, Duppen VV, Caesens P, Denef C, Vankelecom H (2005) The adult pituitary contains a cell population displaying stem/progenitor cell and early embryonic characteristics. Endocrinology 146:3985–3998. https://doi.org/10.1210/en.2005-0185 CrossRefPubMed

11.

Chen J, Gremeaux L, Fu Q, Liekens D, Van Laere S, Vankelecom H (2009) Pituitary progenitor cells tracked down by side population dissection. Stem Cells 27:1182–1195. https://doi.org/10.1002/stem.51 CrossRefPubMed

12.

Lepore DA, Roeszler K, Wagner J, Ross SA, Bauer K, Thomas PQ (2005) Identification and enrichment of colony-forming cells from the adult murine pituitary. Exp Cell Res 308:166–176. https://doi.org/10.1016/j.yexcr.2005.04.023 CrossRefPubMed

13.

Andoniadou CL, Matsushima D, Mousavy Gharavy SN, Signore M, Mackintosh AI, Schaeffer M, Gaston-Massuet C et al (2013) Sox2⁺ stem/progenitor cells in the adult mouse pituitary support organ homeostasis and have tumor-inducing potential. Cell Stem Cell 13:433–445. https://doi.org/10.1016/j.stem.2013.07.004 CrossRefPubMed

14.

Rizzoti K, Akiyama H, Lovell-Badge R (2013) Mobilized adult pituitary stem cells contribute to endocrine regeneration in response to physiological demand. Cell Stem Cell 13:419–432. https://doi.org/10.1016/j.stem.2013.07.006 CrossRefPubMedPubMedCentral

15.

Gleiberman AS, Michurina T, Encinas JM et al (2008) Genetic approaches identify adult pituitary stem cells. Proc Natl Acad Sci USA 105:6332–6337. https://doi.org/10.1073/pnas.0801644105 CrossRefPubMedPubMedCentral

16.

Vankelecom H (2012) Pituitary stem cells drop their mask. Curr Stem Cell Res Ther 7:36–71CrossRefPubMed

17.

Weiss S, Siebzehnrübl FA, Kreutzer J, Blümcke I, Buslei R (2009) Evidence for a progenitor cell population in the human pituitary. Clin Neuropathol 28:309–318CrossRefPubMed

18.

Cheung LY, Davis SW, Brinkmeier ML, Camper SA, Pérez-Millán MI (2017) Regulation of pituitary stem cells by epithelial to mesenchymal transition events and signaling pathways. Mol Cell Endocrinol 445:14–26. https://doi.org/10.1016/j.mce.2016.09.016 CrossRefPubMed

19.

Zhu X, Tollkuhn J, Taylor H, Rosenfeld MG (2015) Notch-Dependent pituitary SOX2(+) stem cells exhibit a timed functional extinction in regulation of the postnatal gland Stem. Cell Rep 5:1196–1209. https://doi.org/10.1016/j.stemcr.2015.11.001 CrossRef

20.

Nantie LB, Himes AD, Getz DR, Raetzman LT (2014) Notch signaling in postnatal pituitary expansion: proliferation, progenitors, and cell specification. Mol Endocrinol 28:731–744. https://doi.org/10.1210/me.2013-1425 CrossRefPubMedPubMedCentral

21.

Goldberg LB, Aujla PK, Raetzman LT (2011) Persistent expression of activated Notch inhibits corticotrope and melanotrope differentiation and results in dysfunction of the HPA axis. Dev Biol 358:23–32. https://doi.org/10.1016/j.ydbio.2011.07.004 CrossRefPubMedPubMedCentral

22.

Olson LE, Tollkuhn J, Scafoglio C, Krones A, Zhang J, Ohgi KA, Wu W et al (2006) Homeodomain-mediated beta-catenin-dependent switching events dictate cell-lineage determination. Cell 125:593–605CrossRefPubMed

23.

Potok MA, Cha KB, Hunt A, Brinkmeier ML, Leitges M, Kispert A, Camper SA (2008) WNT signaling affects gene expression in the ventral diencephalon and pituitary gland growth. Dev Dyn 237:1006–1012. https://doi.org/10.1002/dvdy.21511 CrossRefPubMedPubMedCentral

24.

Chambers TJ, Giles A, Brabant G, Davis JR (2013) Wnt signalling in pituitary development and tumorigenesis. Endocr Relat Cancer 20:R101–R111. https://doi.org/10.1530/ERC-13-0005 CrossRefPubMed

25.

Pyczek J, Buslei R, Schult D, Holsken A, Buchfelder M, Hess I, Hahn H, Uhmann A (2016) Hedgehog signaling activation induces stem cell proliferation and hormone release in the adult pituitary glan. Sci Rep 6:24928. https://doi.org/10.1038/srep24928 CrossRefPubMedPubMedCentral

26.

Abdullah LN, Chow EK (2013) Mechanisms of chemoresistance in cancer stem cells. Clin Transl Med 2:3. https://doi.org/10.1186/2001-1326-2-3 CrossRefPubMedPubMedCentral

27.

Clevers H (2011) The cancer stem cell: premises, promises and challenges. Nat Med 17:313–319. https://doi.org/10.1038/nm.2304 CrossRefPubMed

28.

Magee JA, Piskounova E, Morrison SJ (2012) Cancer stem cells: impact, heterogeneity, and uncertainty. Cancer Cell 21:283–296. https://doi.org/10.1016/j.ccr.2012.03.003 CrossRefPubMedPubMedCentral

29.

Dick J (1996) Normal and leukemic human stem cells assayed in SCID mice. Semin Immunol 8:197–206. https://doi.org/10.1006/smim.1996.0025 CrossRefPubMed

30.

Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, Squire J, Dirks PB (2003) Identification of a cancer stem cell in human brain tumors. Cancer Res 63:5821–5828PubMed

31.

Yang ZF, Ho DW, Ng MN, Lau CK, Yu WC, Ngai P, Chu PW et al (2008) Significance of CD90+ cancer stem cells in human liver cancer. Cancer Cell 13:153–166. https://doi.org/10.1016/j.ccr.2008.01.013 CrossRefPubMed

32.

Dalerba P, Dylla SJ, Park IK, Liu R, Wang X, Cho RW, Hoey T et al (2007) Phenotypic characterization of human colorectal cancer stem cells. Proc Natl Acad Sci USA 104:10158–10163. https://doi.org/10.1073/pnas.0703478104 CrossRefPubMedPubMedCentral

33.

Li C, Heidt DG, Dalerba P, Burant CF, Zhang L, Adsay V, Wicha M et al (2007) Identification of pancreatic cancer stem cells. Cancer Res 67:1030–1037. https://doi.org/10.1158/0008-5472.CAN-06-2030 CrossRefPubMed

34.

Eramo A, Lotti F, Sette G, Pilozzi E, Biffoni M, Di Virgilio A, Conticello C et al (2008) Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ 15:504–514. https://doi.org/10.1038/sj.cdd.4402283 CrossRefPubMed

35.

Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ (2005) Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 65:10946–10951. https://doi.org/10.1158/0008-5472 CrossRefPubMed

36.

Amakye D, Jagani Z, Dorsch M (2013) Unraveling the therapeutic potential of the Hedgehog pathway in cancer. Nat Med 19:1410–1422. https://doi.org/10.1038/nm.3389 CrossRefPubMed

37.

Bao B, Ahmad A, Azmi AS, Ali S, Sarkar FH (2013) Overview of cancer stem cells (CSCs) and mechanisms of their regulation: implications for cancer therapy. Curr Protoc Pharmacol 14(14):25. https://doi.org/10.1002/0471141755.ph1425s61 (Review) PubMedCrossRef

38.

Liu C, Tang DG (2011) MicroRNA regulation of cancer stem cells. Cancer Res 71:5950–5954. https://doi.org/10.1158/0008-5472.CAN-11-1035 CrossRefPubMedPubMedCentral

39.

Plaks V, Kong N, Werb Z (2015) The cancer stem cell niche: how essential is the niche in regulating stemness of tumor cells? Cell Stem Cell 16:225–238. https://doi.org/10.1016/j.stem.2015.02.015 CrossRefPubMedPubMedCentral

40.

Korkaya H, Liu S, Wicha MS (2011) Breast cancer stem cells, cytokine networks, and the tumor microenvironment. J Clin Invest 121:3804–3809. https://doi.org/10.1172/JCI57099 CrossRefPubMedPubMedCentral

41.

Lloyd RV, Hardin H, Montemayor-Garcia C, Rotondo F, Syro LV, Horvath E, Kovacs K (2013) Stem cells and cancer stem-like cells in endocrine tissues. Endocr Pathol 24:1–10. https://doi.org/10.1007/s12022-013-9235-1 CrossRefPubMed

42.

Xu Q, Yuan X, Tunici P, Liu G, Fan X, Xu M, Hu J et al (2009) Isolation of tumour stem-like cells from benign tumours. Br J Cancer 101:303–311. https://doi.org/10.1038/sj.bjc.6605142 CrossRefPubMedPubMedCentral

43.

Hosoyama T, Nishijo K, Garcia MM, Schaffer BS, Ohshima-Hosoyama S, Prajapati SI, Davis MD et al (2010) A postnatal Pax7 progenitor gives rise to pituitary adenomas. Genes Cancer 1:388–402. https://doi.org/10.1177/1947601910370979 CrossRefPubMedPubMedCentral

44.

Yunoue S, Arita K, Kawano H, Uchida H, Tokimura H, Hirano H (2011) Identification of CD133+ cells in pituitary adenomas. Neuroendocrinology 94:302–312. https://doi.org/10.1159/000330625 CrossRefPubMed

45.

Chen L, Ye H, Wang X, Tang X, Mao Y, Zhao Y, Wu Z et al (2014) Evidence of brain tumor stem progenitor-like cells with low proliferative capacity in human benign pituitary adenoma. Cancer Lett 349:61–66. https://doi.org/10.1016/j.canlet.2014.03.031 CrossRefPubMed

46.

Mertens FM, Gremeaux L, Chen J, Fu Q, Willems C, Roose H, Govaere O et al (2015) Pituitary tumors contain a side population with tumor stem cell-associated characteristics. Endocr Relat Cancer 22:481–504. https://doi.org/10.1530/ERC-14-0546 CrossRefPubMed

47.

Würth R, Barbieri F, Pattarozzi A, Gaudenzi G, Gatto F, Fiaschi P, Ravetti JL et al (2016) Phenotypical and pharmacological characterization of stem-like cells in human pituitary adenomas. Mol Neurobiol. https://doi.org/10.1007/s12035-016-0025 (Epub ahead of print) PubMedCrossRef

48.

Orciani M, Davis S, Appolloni G, Lazzarini R, Mattioli-Belmonte M, Ricciuti RA, Boscaro M et al (2015) Isolation and characterization of progenitor mesenchymal cells in human pituitary tumors. Cancer Gene Ther 22:9–16. https://doi.org/10.1038/cgt.2014.63 CrossRefPubMed

49.

Irollo E, Pirozzi G (2013) CD133: to be or not to be, is this the real question? Am J Transl Res 5:563–581PubMedPubMedCentral

50.

Meng X, Li M, Wang X, Wang Y, Ma D (2009) Both CD133+ and CD133 subpopulations of A549 and H446 cells contain cancer-initiating cells. Cancer Sci 100:1040–1046. https://doi.org/10.1111/j.1349-7006.2009.01144.x CrossRefPubMed

51.

Mallard BW, Tiralongo J (2017) Cancer stem cell marker glycosylation: nature, function and significance. Glycoconj J 34:441–452. https://doi.org/10.1007/s10719-017-9780-9 CrossRefPubMed

52.

Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, Deans R et al (2006) Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for cellular therapy position statement. Cytotherapy 8:315–317. https://doi.org/10.1080/14653240600855905 CrossRefPubMed

53.

Orciani M, Caffarini M, Sorgentoni G, Ricciuti RA, Arnaldi G, Di Primio R (2017) Effects of somatostatin and its analogues on progenitor mesenchymal cells isolated from human pituitary adenomas. Pituitary 20:251–260. https://doi.org/10.1007/s11102-016-0770-x CrossRefPubMed

54.

Lum SS, Fletcher WS, O’Dorisio MS, Nance RW, Pommier RF, Caprara M (2001) Distribution and functional significance of somatostatin receptors in malignant melanoma. World J Surg 25:407–412CrossRefPubMed

55.

Megnis K, Mandrika I, Petrovska R, Stukens J, Rovite V, Balcere I, Jansone LS, Peculis R, Pirags V, Klovins J (2016) Functional characteristics of multipotent mesenchymal stromal cells from pituitary adenomas. Stem Cells Int 2016:7103720. https://doi.org/10.1155/2016/7103720 CrossRefPubMedPubMedCentral

56.

Sato R, Semba T, Saya H, Arima Y (2016) Concise review: stem cells and epithelial-mesenchymal transition in cancer: biological implications and therapeutic targets. Stem Cells 34:1997–2007. https://doi.org/10.1002/stem.2406 CrossRefPubMed

57.

Kalluri R, Weinberg RA (2009) The basics of epithelial-mesenchymal transition. J Clin Invest 119:1420–1428. https://doi.org/10.1172/JCI39104 CrossRefPubMedPubMedCentral

58.

Savagner P, Kusewitt DF, Carver EA, Magnino F, Choi C, Gridley T, Hudson LG (2005) Developmental transcription factor slug is required for effective re-epithelialization by adult keratinocytes. J Cell Physiol 202:858–866. https://doi.org/10.1002/jcp.20188 CrossRefPubMed

59.

Kusewitt DF, Choi C, Newkirk KM, Leroy P, Li Y, Chavez MG, Hudson LG (2009) Slug/Snai2 is a downstream mediator of epidermal growth factor receptor-stimulated reepithelialization. J Invest Dermatol 129:49–495. https://doi.org/10.1038/jid.2008.222 CrossRef

60.

Thiery JP (2002) Epithelial–mesenchymal transitions in tumour progression. Nat Rev Cancer 2:442–454. https://doi.org/10.1038/nrc822 CrossRefPubMed

61.

Mani SA, Guo W, Liao M-J, Eaton EN, Ayyanan A, Zhou AY, Brooks M et al (2008) The epithelial—mesenchymal transition generates cells with properties of stem cells. Cell 133:704–715. https://doi.org/10.1016/j.cell.2008.03.027 CrossRefPubMedPubMedCentral

62.

Morel AP, Lie`vre M, Thomas C, Hinkal G, Ansieau S, Puisieux A (2008) Generation of breast cancer stem cells through epithelial–mesenchymal transition. PLoS One 3:e2888. https://doi.org/10.1371/journal.pone.0002888 CrossRefPubMedPubMedCentral

63.

Kong D, Banerjee S, Ahmad A, Li Y, Wang Z, Sethi S, Sarkar FH (2010) Epithelial to mesenchymal transition is mechanistically linked with stem cell signatures in prostate cancer cells. PLoS One 5:e12445. https://doi.org/10.1371/journal.pone.0012445 CrossRefPubMedPubMedCentral

64.

Pirozzi G, Tirino V, Camerlingo R, Franco R, La Rocca A, Liguori E, Martucci N et al (2011) Epithelial to mesenchymal transition by TGFb-1 induction increases stemness characteristics in primary non-small cell lung cancer cell line. PLoS One 6:e21548. https://doi.org/10.1371/journal.pone.0021548 CrossRefPubMedPubMedCentral

65.

Yoon CH, Kim MJ, Lee H, Kim RK, Lim EJ, Yoo KC, Lee GH et al (2012) PTTG1 oncogene promotes tumor malignancy via epithelial to mesenchymal transition and expansion of cancer stem cell population. J Biol Chem 287:19516–19527. https://doi.org/10.1074/jbc.M111.337428 CrossRefPubMedPubMedCentral

66.

Liu X, Fan D (2015) The epithelial-mesenchymal transition and cancer stem cells: functional and mechanistic links. Curr Pharm Des 21:1279–1291CrossRefPubMed

67.

Davis SW, Keisler JL, Perez-Millan MI, Schade V, Camper SA (2016) All hormone-producing cell types of the pituitary intermediate and anterior lobes derive from Prop1-expressing progenitors. Endocrinology 157:1385–1396. https://doi.org/10.1210/en.2015-1862 CrossRefPubMedPubMedCentral

68.

Pérez Millàn MI, Brinkmeier ML, Mortensen AH, Camper SA (2016) PROP1 triggers epithelial-mesenchymal transition-like process in pituitary stem cells. Elife 5:e14470. https://doi.org/10.7554/eLife.14470 CrossRefPubMedPubMedCentral

69.

Carreno G, Gonzalez-Meljem JM, Haston S, Martinez-Barbera JP (2016) Stem cells and their role in pituitary tumorigenesis. Mol Cell Endocrinol 445:27–34. https://doi.org/10.1016/j.mce.2016.10.005 CrossRefPubMed

Title: Pituitary adenomas, stem cells, and cancer stem cells: what’s new?
Authors: M. Caffarini
M. Orciani
L. Trementino
R. Di Primio
G. Arnaldi
Publication date: 01-07-2018
Publisher: Springer International Publishing
Published in: Journal of Endocrinological Investigation / Issue 7/2018
Electronic ISSN: 1720-8386
DOI: https://doi.org/10.1007/s40618-017-0803-y

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 7/2018

Impaired taste sensation in type 2 diabetic patients without chronic complications: a case–control study

Copeptin and insulin resistance: effect modification by age and 11 β-HSD2 activity in a population-based study

One-hour post-load plasma glucose level is associated with a worse metabolic profile in children with GH deficiency

Long-term response to recombinant human growth hormone treatment: a new predictive mathematical method

Age-specific reference values and cut-off points for anti-müllerian hormone in infertile women following a long agonist treatment protocol for IVF

Transoral thyroidectomy: a viable surgical option with unprecedented complications—a case series

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage